4D Lifetec's revolutionary cancer diagnostics spotlighted in World Pharma Today

Uncover the forefront of cancer diagnostics with 4D Lifetec's cutting-edge technologies, showcased in the esteemed pages of World Pharma Today. CEO Dr. Giancarlo Rizzoli unveils our revolutionary approach, promising to redefine the landscape of healthcare. Delve into the article to explore the innovative methodologies driving our vision and the immense potential they hold for the future of medical diagnostics.

Read more...

4D Lifetec secures CHF 23.3 Mio in a share and investment deal with Xlife Sciences opening new horizons in using AI and digital health in early cancer detection.

18.10.2023   In a significant financial milestone, Xlife Sciences AG invests CHF 23.3 million in 4D Lifetec AG, acquiring a 20% stake in the company. With the agreement signed today, Xlife Sciences is not only bringing in a direct cash investment, but also an AI software developed specifically for 4D Lifetec, which will massively expand the functionality of the 4D Lifetest™ in the field of digital health. The strategic investment marks a significant turning point in the healthcare industry as it combines financial strength with cutting-edge technology to revolutionize early cancer detection.

Read more...

November 2022 - 4D Lifetec and Molecular Diagnostics Group announce strategic partnership to further industrialization of 4D Lifetest™ liquid biopsy assay

4D Lifetec Ltd. and the German Molecular Diagnostics Group (MDG) announce that they have signed a non-exclusive master collaboration agreement. The goal of the collaboration is to further industrialize the 4D Lifetest™, a novel blood test for the early detection of cancer. Planned joint projects include industrial production of the assay kits and automation of the 4D Lifetest™ wetlab workflow to unlock its high-throughput potential for screening applications. 

Read more...

June 2022 - Press Release: 4D Lifetec announces successful first closing of CHF 1.9 million Series B financing to launch its early lung cancer detection liquid biopsy assay 4D Lifetest™ Lung Dx in Europe.

4D Lifetec AG, a privately-held Swiss diagnostics company focusing on the development and marketing of early stage liquid biopsy cancer diagnostics, announced today that it has raised CHF 1.9 million in a first closing of its Series B round.

 

To read the press release click here.

Read more...

November 2020 - 4D Lifetec publishes first clinical results at the 39th World Cancer Conference

In an observational study 'Prospective Evaluation of 4D LifetestTM Parameters to Develop a Universal Early Cancer Diagnosis Test', blood samples from 39 participants were collected (49% patients with newly diagnosed, untreated lung cancer and 51% non-cancer). Evaluation of our DDS biomarker (DNA Damage Sensitivity) comparing non-cancer with cancer samples resulted in more than 90% sensitivity at 95% specificity (95% CI: 76.4-99.7%) across all stages.

Read more...